HCW Biologics Inc. (HCWB)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.26
- As of
Kresmion compiles this page from HCWB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
HCW Biologics Inc. (HCWB): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-24.
See the full HCWB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HCWB on one page. Preview it with sample data, then open it live with a free account.
Preview the HCWB dossierActive signals for HCWB
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 400.6%, EPS $-10.11 vs $-2.0196 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in HCWB
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 257.1% - EPS $-18.36 vs $-5.1408 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 182.4% - EPS $2.22 vs $-2.6928 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 158.8% - EPS $-1.08 vs $1.836 estimate
FREE, NO ACCOUNT
Every signal on HCWB, as it fires
You are seeing 5 of 11 signals recorded on HCWB since 2026-05-27.
The five above landed across 4 days. The other 6 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in HCWB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 40423R303 · 2026Q2 | $100K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, HCWB
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
HCWB against its peers
HCWB's operating margin of -24270.7% ranks in the 23rd percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | HCWB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 54232 USD | 245350 USD | 35 | 12 |
| Gross margin | 20.0% | 79.1% | 17 | 8 |
| Operating margin | -24270.7% | -3270.0% | 23 | 10 |
| Net margin | -14677.1% | -3189.7% | 23 | 10 |
| Return on equity | -287.9% | -212.7% | 36 | 17 |
| 1 year | -95.0% | -92.9% | 32 | 13 |
Peers (21): MBIO, ONCO, CVKD, CLDI, SXTP, APVO, REVB, JUNS, BRTX, PPCB, ERNA, ADTX, GRI, MTNB, PMCB, VIVS, SILO, PCSA, EMMA, GOVX, APTOF. Left out: MLEC (period gap), XRTX (no annual filing), NYMXF (period gap), ENLV (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (HCWB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow HCWB on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to HCWB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.